LEMAITRE VASCULAR INC (LMAT) Stock Overview
USA - NASDAQ:LMAT - US5255582018 - Common Stock
LMAT Key Statistics, Chart & Performance
The current stock price of LMAT is 89.21 USD. In the past month the price increased by 5.96%. In the past year, price increased by 4.17%.
LMAT Latest News, Press Relases and Analysis
LMAT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.42 | 220.78B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.47 | 195.91B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.27 | 149.82B | ||
| SYK | STRYKER CORP | 29.71 | 145.96B | ||
| MDT | MEDTRONIC PLC | 16.94 | 120.15B | ||
| BDX | BECTON DICKINSON AND CO | 13.02 | 53.26B | ||
| IDXX | IDEXX LABORATORIES INC | 53.36 | 51.27B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.61 | 44.68B | ||
| RMD | RESMED INC | 27.17 | 37.87B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.77 | 35.68B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.26 | 27.76B | ||
| DXCM | DEXCOM INC | 41.37 | 27.58B |
Related stock screener links
About LMAT
Company Profile
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 651 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
Company Info
LEMAITRE VASCULAR INC
63 2nd Ave
Burlington MASSACHUSETTS 01803 US
CEO: George W. LeMaitre
Employees: 658
Phone: 17812212266
LEMAITRE VASCULAR INC / LMAT FAQ
What does LEMAITRE VASCULAR INC do?
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 651 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
Can you provide the latest stock price for LEMAITRE VASCULAR INC?
The current stock price of LMAT is 89.21 USD. The price increased by 0.22% in the last trading session.
Does LEMAITRE VASCULAR INC pay dividends?
LEMAITRE VASCULAR INC (LMAT) has a dividend yield of 0.9%. The yearly dividend amount is currently 0.64.
What is the ChartMill technical and fundamental rating of LMAT stock?
LMAT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the upcoming dividend date for LEMAITRE VASCULAR INC?
The next ex-dividend date for LEMAITRE VASCULAR INC (LMAT) is August 21, 2025.
Is LEMAITRE VASCULAR INC (LMAT) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LMAT.
What is the market capitalization of LMAT stock?
LEMAITRE VASCULAR INC (LMAT) has a market capitalization of 2.02B USD. This makes LMAT a Mid Cap stock.
LMAT Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to LMAT. When comparing the yearly performance of all stocks, LMAT turns out to be only a medium performer in the overall market: it outperformed 56.81% of all stocks.
LMAT Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to LMAT. Both the health and profitability get an excellent rating, making LMAT a very profitable company, without any liquidiy or solvency issues.
LMAT Financial Highlights
Over the last trailing twelve months LMAT reported a non-GAAP Earnings per Share(EPS) of 2.06. The EPS increased by 23.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 20.08% | ||
| ROA | 8.16% | ||
| ROE | 12.99% | ||
| Debt/Equity | 0.46 |
LMAT Forecast & Estimates
17 analysts have analysed LMAT and the average price target is 106.87 USD. This implies a price increase of 19.8% is expected in the next year compared to the current price of 89.21.
For the next year, analysts expect an EPS growth of 19.93% and a revenue growth 13.86% for LMAT